Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2025-12-25 @ 2:34 AM
NCT ID:
NCT05598034
Eligibility Criteria:
Inclusion Criteria:
1. Age between 20 to 55 years, inclusive
2. Gender: all
3. Race/ethnicity: all races and ethnic groups
4. Capacity to provide informed consent
5. Hamilton Rating Scale for Depression score of ≥17 and \<24, with or without symptoms of anxiety.
6. Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclic's (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention.
7. Work at UCLA or live within 1-hr driving distance of UCLA
Exclusion Criteria:
1. Pregnancy
2. Non-English speaking (due to scales administered)
3. Substance Use Disorder within last 12 months
4. Neurological condition associated with brain abnormalities (e.g., traumatic brain injury; recent stroke, tumor)
5. Any contraindication to tDCS (e.g., skin disease or treatment causing irritation)
6. Any condition that would contraindicate scanning (metal implants, claustrophobia or a breathing or movement disorder)
7. Currently receiving any form of psychotherapy
8. Change in antidepressant medication within 6-weeks of starting the trial
9. Severe or treatment resistant depression - HAMD scores \> 24 and a history of a major depressive episode lasting \>2- years or failure to 2 or more antidepressant trials in the current index episode
10. Any neuromodulation therapy (e.g., ECT, rTMS, DBS, VNS or tDCS) within the last 3-months
11. Current or past (within the last 1-month) use of anticonvulsants, lithium, psychostimulant, dexamphetamine
12. Current use of decongestants or other medication previously shown to interfere with cortical excitability
13. Diagnosis: Schizophrenia Axis I disorder, or dementia of any type
14. Bipolar I disorder (due to possible risk of mania and because lithium and anticonvulsants are excluded).
15. On regular benzodiazepine medication that it is not clinically appropriate to discontinue for the 2-week duration of the trial
16. Depression related to serious medical illness (i.e., mood disorder due to general medical condition) 17. Actively suicidal as defined by a score of 4 on item 3 of HAMD
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
55 Years
Study:
NCT05598034
Study Brief:
Protocol Section:
NCT05598034